Bioventus Launches DUROLANE in the US

DURHAM, NC – March 5, 2018 – Bioventus, a global leader in orthobiologic solutions, today launched DUROLANE, its single-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA). DUROLANE joins three-injection HA GELSYN-3™ and the five-injection HA SUPARTZ FX™ in the company’s OA portfolio making Bioventus the only orthobiologics company in the US with a single, three and five-injection HA option for treatment of knee OA.

“Introducing DUROLANE to the US market gives patients, physicians and payers access to a proven pain reliever for knee OA that has improved the lives of more than 1 million people worldwide,” said Tony Bihl, CEO of Bioventus. “In addition, DUROLANE is very safe for patients and has more level-1 clinical studies than any other single-injection HA knee therapy on the market today.” 

Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. Knee osteoarthritis involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues within the knee.  DUROLANE has been proven to provide greater reduction in knee pain versus Synvisc-One® and longer lasting pain relief versus a steroid injection2. DUROLANE is also safe for repeated courses of therapy. Repeated use of DUROLANE does not increase the incidence of adverse events.